Braeburn Pharmaceuticals

Out licensing

Braeburn is developing drugs to fight against opioid addiction. Opioid overdose and misuse are a significant public health crisis in the US today affecting 2 million people. To treat opioid addiction, Braeburn is developing a FluidCrystal® injection depot technology, a next generation delivery system that includes a lipid-based liquid with a dissolved active ingredient. Braeburn is adapting this technology to deliver buprenorphine, a medication that normalizes brain chemistry and blocks the euphoric effects of opioids relieving physiological cravings without negative effects. The extended-release injected therapy of buprenorphine for weekly and monthly subcutaneous injections for moderate to severe opioid use disorder was recently accepted by the FDA.